IRD
NASDAQ · Biotechnology
Opus Genetics Inc
$4.85
-0.20 (-3.96%)
Open$5.08
Previous Close$5.05
Day High$5.16
Day Low$4.83
52W High$7.07
52W Low$1.50
Volume—
Avg Volume2.67M
Market Cap396.01M
P/E Ratio—
EPS$-1.29
SectorBiotechnology
Analyst Ratings
Strong Buy
23 analysts
Price Target
+378.6% upside
Current
$4.85
$4.85
Target
$23.21
$23.21
$16.63
$23.21 avg
$31.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.56M | 26.18M | 29.63M |
| Net Income | -64,809,375 | -82,280,205 | -1,185,756 |
| Profit Margin | -349.3% | -331.9% | -4.0% |
| EBITDA | -50,375,669 | -67,508,655 | -1,569,658 |
| Free Cash Flow | — | — | -1,455,645 |
| Rev Growth | -29.1% | -29.1% | +20.7% |
| Debt/Equity | 0.07 | 0.07 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |